Mirae Asset Global Investments Co., Ltd. Biotechnology

Mirae Asset Global Investments Co., Ltd.

$24 Billion
Q4 2024

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
ABSI Absci Corp	$344M	$10,000 0.0% of portfolio	3,827	Q4 2024 New
PGEN Precigen, Inc.	$271M	$10,000 0.0% of portfolio	9,759	Q4 2024 Reduced 6.22%
SLN Silence Therapeutics PLC	$182M	$10,000 0.0% of portfolio	1,566	Q4 2024 New
TRVI Trevi Therapeutics, Inc.	$236M	$10,000 0.0% of portfolio	2,561	Q4 2024 New
VYGR Voyager Therapeutics, Inc.	$206M	$10,000 0.0% of portfolio	1,820	Q4 2024 Reduced 7.71%
AVIR Atea Pharmaceuticals, Inc.	$243M	$9,000 0.0% of portfolio	2,815	Q4 2024 Reduced 7.8%
ELYM Eliem Therapeutics, Inc.	$109M	$9,000 0.0% of portfolio	2,240	Q4 2024 New
ITOS I Teos Therapeutics, Inc.	$262M	$9,000 0.0% of portfolio	1,217	Q4 2024 Reduced 7.87%
VNDA Vanda Pharmaceuticals Inc.	$244M	$9,000 0.0% of portfolio	1,943	Q4 2024 Reduced 7.83%
FDMT 4 D Molecular Therapeutics, Inc.	$192M	$8,000 0.0% of portfolio	1,540	Q4 2024 Reduced 18.09%
ACIU Ac Immune Sa	$225M	$8,000 0.0% of portfolio	3,296	Q4 2024 Reduced 7.86%
AMLX Amylyx Pharmaceuticals, Inc.	$212M	$8,000 0.0% of portfolio	2,284	Q4 2024 Reduced 7.23%
CCCC C4 Therapeutics, Inc.	$164M	$8,000 0.0% of portfolio	2,352	Q4 2024 New
FHTX Foghorn Therapeutics Inc.	$166M	$8,000 0.0% of portfolio	1,853	Q4 2024 New
LRMR Larimar Therapeutics, Inc.	$159M	$8,000 0.0% of portfolio	2,126	Q4 2024 New
LXRX Lexicon Pharmaceuticals, Inc.	$138M	$8,000 0.0% of portfolio	12,046	Q4 2024 Reduced 7.86%
RVNC Revance Therapeutics, Inc.	$212M	$8,000 0.0% of portfolio	3,496	Q4 2024 Reduced 7.78%
KMPH Kempharm, Inc	$170M	$8,000 0.0% of portfolio	1,779	Q4 2024 New
ALEC Alector, Inc.	$135M	$6,000 0.0% of portfolio	3,263	Q4 2024 Reduced 7.3%
AMRN Amarin Corp Plcuk	$222M	$6,000 0.0% of portfolio	13,338	Q4 2024 Reduced 7.84%
FATE Fate Therapeutics Inc	$127M	$6,000 0.0% of portfolio	3,795	Q4 2024 New
IGMS Igm Biosciences, Inc.	$41.4M	$6,000 0.0% of portfolio	1,136	Q4 2024 New
MGNX Macrogenics Inc	$175M	$6,000 0.0% of portfolio	2,091	Q4 2024 Reduced 7.84%
TSVT 2seventy Bio, Inc.	$98.1M	$5,000 0.0% of portfolio	1,719	Q4 2024 New
INZY Inozyme Pharma, Inc.	$56.2M	$5,000 0.0% of portfolio	2,141	Q4 2024 New
LYEL Lyell Immunopharma, Inc.	$149M	$5,000 0.0% of portfolio	9,305	Q4 2024 Added 0.5%
MRSN Mersana Therapeutics, Inc.	$55.4M	$5,000 0.0% of portfolio	4,117	Q4 2024 New
NKTX Nkarta, Inc.	$106M	$5,000 0.0% of portfolio	2,352	Q4 2024 New
SCPH Sc Pharmaceuticals Inc.	$88M	$5,000 0.0% of portfolio	1,668	Q4 2024 New
STRO Sutro Biopharma, Inc.	$99.1M	$5,000 0.0% of portfolio	2,748	Q4 2024 New
BMEA Biomea Fusion, Inc.	$115M	$4,000 0.0% of portfolio	1,208	Q4 2024 Reduced 7.79%
ENTA Enanta Pharmaceuticals Inc	$107M	$4,000 0.0% of portfolio	706	Q4 2024 New
PEPG Pep Gen Inc.	$29.5M	$4,000 0.0% of portfolio	1,086	Q4 2024 New
TCRX T Scan Therapeutics, Inc.	$46.9M	$4,000 0.0% of portfolio	1,636	Q4 2024 New
APLT Applied Therapeutics Inc.	$27.4M	$3,000 0.0% of portfolio	3,877	Q4 2024 New
EDIT Editas Medicine, Inc.	$87.3M	$3,000 0.0% of portfolio	2,751	Q4 2024 Reduced 7.78%
PYXS Pyxis Oncology, Inc.	$54M	$3,000 0.0% of portfolio	1,982	Q4 2024 New
SBTX Silverback Therapeutics, Inc.	$0	$0 0.0% of portfolio	3,239	Q4 2024 Reduced 7.62%

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mirae Asset Global Investments Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Mirae Asset Global Investments Co., Ltd. with notifications on news.